Filing Details
- Accession Number:
- 0001104659-19-037459
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-25 18:05:21
- Reporting Period:
- 2019-06-24
- Accepted Time:
- 2019-06-25 18:05:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1687880 | Versant Venture Capital Vi, L.p. | C/O Akero Therapeutics, Inc. 170 Harbor Way, 3Rd Floor South San Francisco CA 94080 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-24 | 3,469,759 | $0.00 | 3,469,759 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-06-24 | 235,099 | $0.00 | 3,704,858 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-06-24 | 400,000 | $16.00 | 4,104,858 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-06-24 | 10,666,667 | $0.00 | 3,469,759 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-06-24 | 722,737 | $0.00 | 235,099 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Represents the total number of shares of common stock received by Versant Venture Capital VI, L.P. ("Versant VI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
- All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
- Represents the total number of shares of common stock received by Versant VI upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
- These shares are owned directly by Versant VI. Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI.
- On June 24, 2019, Versant VI purchased 400,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
Billionaire Hedge Funds
